{"filings":[{"id":91742,"accession_number":"0001104659-26-050317","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","2.02","9.01","7.01","8.01"],"status":"ready","headline":"CareDx acquires Naveris for $160M; Q1 revenue $118M (+39% YoY), raises 2026 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash $160M for Naveris, plus up to $100M in revenue milestones; expands into viral-mediated cancer MRD surveillance.","Q1 revenue $118M (+39% YoY); Testing Services revenue $91M (+48% YoY); GAAP net income $3M vs loss $10M prior year.","FY2026 revenue guidance raised to $447M-$465M from $420M-$444M; AEBITDA guidance raised to $43M-$57M.","Board authorized up to $100M stock repurchase program over 24 months.","Deal expected to close Q3 2026; neutral to FY2026 AEBITDA; Naveris $34M revenue in 2025 with 65% gross margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91740,"accession_number":"0001217234-26-000024","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K/A","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CareDx grants Keith Kennedy 48,268 RSUs and PRSUs for expanded CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["24,134 RSUs approved; one-third vest 4/6/27, then quarterly over three years.","24,134 PRSUs with performance targets for 2026-2027; payout 0-200% of target.","Base salary of $613,000 and 75% target bonus unchanged.","Grants under 2024 Equity Incentive Plan; additional to existing COO awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91741,"accession_number":"0001104659-26-043970","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"CareDx sells Lab Products to Eurobio for $170M; Q1 rev up 39% to $118M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Divests Lab Products (IVD kits) to Eurobio Scientific for $170M cash; expected close by end of Q3 2026.","Preliminary Q1 2026 revenue ~$118M (+39% YoY); Testing Services revenue ~$91M (+48% YoY) on volume of ~54,900 (+17%).","Patient & Digital Solutions revenue ~$16M (+33% YoY); Lab Products revenue ~$10M (-4% YoY).","Cash, equivalents, and marketable securities ~$198M as of Mar 31, 2026.","Retains exclusive North American distribution rights for certain Eurobio post-transplant monitoring IVD tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102027,"accession_number":"0001217234-26-000019","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K/A","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01","5.02","7.01"],"status":"ready","headline":"CareDx Q4 rev $108M +25% YoY, FY25 rev $380M; FY26 guide $420-444M; CFO resigns, Kennedy appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $108M (+25% YoY); full-year revenue $380M (+14%). FY2026 guidance $420-444M.","Q4 GAAP net loss $4M vs $88M income (prior year had $96M litigation reversal); FY25 GAAP loss $21M; adj. EBITDA $32M.","Testing services Q4 rev $78M (+23%), volume ~53K tests (+17%); full-year rev $275M.","CFO Nathan Smith resigns for personal reasons; Keith Kennedy (COO since Sept 2024) appointed CFO & COO effective Feb 26.","Smith separation: 9 months base salary, $91,643 bonus, COBRA reimbursement, and 5,840 RSUs vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":379805000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102029,"accession_number":"0001217234-26-000015","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01","5.02","7.01"],"status":"ready","headline":"CareDx Q4 revenue up 25% to $108M, guides FY2026 revenue $420M-$444M; CFO resigns, Kennedy appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 revenue $380M (+14% YoY); Q4 revenue $108M (+25% YoY).","Q4 GAAP net loss $4M vs net income $88M in Q4 2024; non-GAAP net income $6M ($0.12 diluted EPS).","FY2026 revenue guidance $420M-$444M; cash $201M, share repurchases $88M in 2025.","CFO Nathan Smith resigns effective Feb 25, 2026 for personal reasons; receives severance of 9 months salary plus $91,643 bonus and RSU vesting.","Keith Kennedy appointed CFO and COO effective Feb 26, 2026; previously COO since Sep 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":379805000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102028,"accession_number":"0001217234-26-000007","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CareDx prelim Q4 revenue ~$108M (+25% YoY); FY25 rev ~$380M (+14%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 testing services volume ~53,000 (+17% YoY); testing revenue ~$78M (+23%).","Patient & digital solutions revenue ~$17M (+47%); product revenue ~$13M (+17%).","Full-year 2025 revenue ~$380M; testing volume ~200,000 (+14%).","Share repurchases: $88M for 5.8M shares in 2025; $12M for 773K shares in Q4.","Cash, equivalents, and securities ~$200M as of Dec 31, 2025; no FY26 guidance given."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":379805000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118371,"accession_number":"0001217234-25-000072","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court preliminarily approves CareDx shareholder derivative settlement with governance reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Preliminary approval granted Dec 9 for settlement of Edelman v. Bickerstaff derivative action alleging false testing revenue statements.","Settlement requires CareDx to implement governance reforms (audit committee, disclosure committee, compliance review) for 4 years.","Compliance assessment budget of $250k in FY2026; $250k/year for FY2027-28 for implementation and monitoring.","Plaintiffs' counsel may seek up to $1.2M in fees/expenses (opposed by defendants); no monetary recovery for shareholders.","Final approval hearing set for June 30, 2026; settlement also resolves related Delaware derivative action (Burns IRA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118370,"accession_number":"0001217234-25-000068","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"CareDx changes director election standard to majority vote; adopts resignation policy","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended bylaws on Dec 12, 2025, switching director election standard from plurality to majority vote.","Majority standard applies in uncontested elections; plurality still used in contested elections.","Incumbent director failing to receive majority must submit resignation; Governance Committee reviews within 90 days.","Board will publicly disclose its decision on the resignation recommendation after review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118369,"accession_number":"0001217234-25-000062","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"CareDx Q3 revenue $100.1M (+21% YoY), turns to GAAP net income $1.7M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $100.1M, up 21% YoY; testing services volume ~50,300 (+13% YoY).","GAAP net income $1.7M vs loss $10.6M in Q3 2024; adjusted EBITDA $15.3M vs $6.9M.","Raised FY 2025 revenue guidance to $372M-$376M (from $367M-$373M); raised adj. EBITDA guidance to $35M-$39M.","Cash $194.2M, no debt; repurchased $25.6M shares during quarter.","Appointed new CMO Jeff Teuteberg, MD and board member Suresh Gunasekaran."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":271419000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118368,"accession_number":"0001217234-25-000051","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CareDx appoints Suresh Gunasekaran to board of directors effective Oct 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Suresh Gunasekaran as Class II director; he is CEO and President of UCSF Health.","Prior roles include CEO of University of Iowa Hospitals & Clinics and leadership at UT Southwestern.","Receives $50k annual cash retainer (electable in cash or stock) plus initial RSU grant of $400k vesting over 3 years.","Standard annual RSU grant of $225k on day after each annual meeting, vesting in one year or before next meeting.","No family relationships or arrangements with any person; standard indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134806,"accession_number":"0001217234-25-000045","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01","5.02","7.01"],"status":"ready","headline":"CareDx Q2 adjusted revenue up 14% YoY to $90.5M; narrows FY guidance; appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 adjusted revenue $90.5M (+14% YoY); GAAP revenue $86.7M (-6% YoY) due to $3.8M aged receivable write-off.","Testing services volume ~49,500 (+13% YoY); AlloSure Kidney volume up ~20% YoY.","GAAP net loss $8.6M ($0.16/sh) vs $4.6M loss; non-GAAP net income $5.6M ($0.10/sh) vs $13.6M.","Adjusted EBITDA $9.1M (excl. $3.8M write-off) vs prior year loss $0.3M.","CFO change: Nathan Smith appointed, effective Aug 7, 2025; Abhishek Jain retired; Smith receives $400K salary, RSUs, PSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":171364000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151727,"accession_number":"0001193125-25-139978","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CareDx shareholders approve equity plan increase of 1.6M shares at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted to amend 2024 Equity Incentive Plan, adding 1,600,000 shares (~3% dilution).","Elected Fred E. Cohen and R. Bryan Riggsbee as Class II directors to serve until 2026.","Ratified Deloitte & Touche as independent auditor for FY2025 with 99.8% support.","Advisory say-on-pay resolution approved with 40.0M votes for and 3.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151726,"accession_number":"0001193125-25-134150","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CareDx completes $50M buyback (5% shares), authorizes new $50M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed $50M repurchase of ~3.03M shares, representing 5% of outstanding common stock.","Board authorized new $50M share repurchase program effective June 5, 2025, for up to 24 months.","Q1 2025 revenue $84.7M (+18% YoY); cash and no debt at $231M.","CEO reaffirms long-term target of $500M revenue and 20% adjusted EBITA by 2027.","Seventh consecutive quarter of testing services volume growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151725,"accession_number":"0001217234-25-000036","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CareDx Q1 revenue $84.7M (+18% YoY); GAAP net loss narrows to $10.4M; non-GAAP net income $5.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $84.7M (+18% YoY); testing services revenue $61.9M (+15%), volume ~47,100 (+12% YoY).","GAAP net loss $10.4M ($0.19 loss per share) vs $19.9M ($0.38) prior year; non-GAAP net income $5.4M ($0.09 diluted).","Adjusted EBITDA $4.6M vs loss $1.9M; cash $231M, no debt.","Reaffirms FY2025 revenue guidance $365-375M, adjusted EBITDA $29-33M; 2027 targets $500M rev, $100M EBITDA.","Launched AlloSure Heart for pediatric and AlloSure Kidney for SPK; presented AlloHeme data at TANDEM and EBMT."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":84685000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170582,"accession_number":"0001217234-25-000016","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CareDx enters amended change-of-control severance deal with CFO Abhishek Jain","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Abhishek Jain gets 12 months base salary lump sum, full equity vesting, and target bonus upon qualifying termination 3 months before or 12 months after a change of control.","Outside the change-of-control period, Jain receives 12 months base salary paid periodically plus 12 months COBRA reimbursement.","New agreement dated March 27, 2025, supersedes the prior 2022 agreement and remains in effect while Jain is employed.","If termination occurs before first anniversary, equity awards vest pro rata for the initial 25% cliff tranche only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170581,"accession_number":"0001217234-25-000007","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"CareDx Q4 revenue $86.6M (+32% YoY), FY2025 guidance $365-375M; $50M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $86.6M (+32% YoY); testing services revenue $63.8M (+37%); volume ~45,500 tests (+14%).","Q4 GAAP net income $87.7M ($1.51 diluted EPS) vs loss $118.1M in Q4 2023; non-GAAP net income $10.7M ($0.18).","Full year revenue $333.8M (+19%); net income $52.5M (incl. $96.3M litigation reversal); adj. EBITDA $27.8M.","Board authorized $50M stock buyback over up to 24 months. Cash $261M, no debt as of Dec 31, 2024.","FY2025 revenue guidance $365M-$375M (9-12% growth); CEO cites 'transformative year' and long-term growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":333785000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170580,"accession_number":"0001193125-25-004941","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"CareDx reports preliminary Q4 revenue up 30% YoY to ~$85.5M; guides 2025 revenue $370M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue expected $85M-$86M, up ~30% YoY; testing services revenue $62.5M-$63.5M, up 35%.","Full year 2024 revenue $332M-$333M; GAAP loss $58M-$60M; adjusted EBITDA gain $25M-$26M.","Testing services volume ~45,500 in Q4, up 14% YoY; sixth consecutive quarter of volume growth.","Cash, equivalents, and marketable securities ~$261M as of Dec 31, 2024, up $26M YoY.","2025 revenue guidance of $370M; targeting $500M revenue and 20% adjusted EBITDA by 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":333785000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170579,"accession_number":"0001193125-25-003535","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CareDx amends outside director compensation policy, accelerates vesting, drops chair retainer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual NSO and RSU awards vest fully on day before next annual meeting if before one-year anniversary.","Removed quarterly retainers for Chairperson Michael Goldberg for his additional CEO Office duties.","Updated references from predecessor equity plan to current 2024 Equity Incentive Plan.","Amendments adopted by Compensation Committee effective January 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187573,"accession_number":"0001217234-24-000101","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CareDx Q3 revenue $82.9M (+23% YoY), raises FY guidance to $327-331M with positive EBITDA $6.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $82.9M (+23% YoY); testing services rev $60.8M (+27%); volume 44,600 tests (+16%).","GAAP net loss $7.4M improved from -$23.5M; non-GAAP net income $8.0M; positive adjusted EBITDA $6.9M.","Raised FY2024 revenue guidance to $327-331M (from $320-328M) and adjusted EBITDA to $18-22M (from $9-15M).","DOJ concluded investigation with no finding of wrongdoing; CMS reaffirmed coverage for AlloSure/AlloMap.","Cash $241M, no debt; hired new COO, CCO, and Chief Data/AI Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":247206000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187572,"accession_number":"0001193125-24-237218","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"CareDx reports preliminary Q3 revenue of $82-83M, up 23% YoY; testing volume rises 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 2024 revenue $82-83M, up ~23% YoY; testing services $60-61M (+26%).","Testing volume ~44,600 tests, up ~16% YoY; includes $1.2M from prior quarters.","Patient & Digital Solutions rev ~$11.9M (+20%); Products rev ~$10.2M (+7%).","Cash and marketable securities ~$240M, no debt; strong balance sheet.","Full Q3 results to be reported on November 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":247206000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187571,"accession_number":"0001193125-24-234155","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CareDx: DOJ declines to intervene in qui tam, closes investigation; SEC closes probe","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Oct 7, 2024, DOJ notified court it declines to intervene in qui tam filed by former employee; investigation closed.","SEC concluded its investigation on Sep 19, 2023, and will not recommend enforcement action.","Company denies qui tam allegations and will vigorously defend if private plaintiff pursues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187570,"accession_number":"0001217234-24-000089","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CareDx President of Patient and Testing Services Alexander Johnson departs; receives $817,920 in cash severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alexander Johnson, President of Patient and Testing Services, separated without cause on Sept 13, 2024.","Will receive 6 months base salary plus COBRA premiums, and $517,920 lump sum (200% of 2024 target bonus).","Also receives $300,000 unpaid retention bonus payable in Dec 2024.","Signed consulting agreement for up to 40 hrs/month for 6 months; fee $107,901 plus equity vesting.","Subject to 12-month non-solicitation of employees and mutual non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204049,"accession_number":"0001193125-24-217626","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CareDx appoints Keith Kennedy COO, Jessica Meng CCO; President Alexander Johnson departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Kennedy named COO effective Sept 12, 2024; base salary $575,000 plus bonus up to 60%.","Kennedy receives inducement Option ($2M) and RSUs ($2M) vesting over four years.","Jessica Meng appointed Chief Commercial Officer; Marica Grskovic named Chief Strategy Officer.","President of Patient and Testing Services Alexander Johnson departs Sept 13; separation terms pending.","Company plans Investor Day in October 2024 to share long-term growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204048,"accession_number":"0001217234-24-000081","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CareDx Q2 revenue $92.3M (+31% YoY); raises FY2024 revenue guidance to $320-$328M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $92.3M (+31% YoY); Testing Services revenue $70.9M (+33%); volume 43,700 tests (+17%).","GAAP net loss narrowed to $1.4M from $25M; non-GAAP net income $13.6M (vs loss of $9.9M).","Adjusted EBITDA positive $12.9M vs loss of $10.4M; cash $228.9M, no debt.","Raised FY2024 revenue guidance to $320-$328M (from $274-$282M); adjusted EBITDA guidance to $9-$15M gain.","Expanded coverage by 27M lives in H1 2024; published SHORE study and Nature Medicine data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":164323000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220757,"accession_number":"0001217234-24-000071","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CareDx stockholders elect three Class I directors and approve 2024 Equity Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["George W. Bickerstaff III, Christine M. Cournoyer, and Hannah Valantine, M.D. elected as Class I directors, terms expiring 2027.","Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2024, with 47.1M votes for.","Advisory approval of named executive officer compensation: 38.9M for, 1.6M against.","2024 Equity Incentive Plan approved (23.4M for, 16.6M against); authorizes up to 3.5M shares for equity awards.","Approximately 91% of outstanding shares (47.4M of 52.0M) represented at meeting, establishing strong quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220756,"accession_number":"0001217234-24-000062","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CareDx Q1 revenue $72M (-7% YoY); raises FY2024 revenue guidance to $274-282M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $72.0M, down 7% YoY from $77.3M but up 10% sequentially from Q4 2023.","Net loss $16.7M ($0.32 loss per share) improved from $23.7M loss ($0.44) a year ago.","Testing Services revenue $53.8M, down 13% YoY but up 15% sequentially; patient results ~42,000, up 6% sequentially.","Adjusted EBITDA loss $1.9M vs $6.4M loss in Q1 2023 and $10.3M loss in Q4 2023.","Raises FY2024 revenue guidance to $274-282M; cash $216M with no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":72049000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220755,"accession_number":"0001193125-24-097776","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CareDx appoints John W. Hanna as President and CEO effective April 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Hanna appointed CEO and Class III director, effective April 15, 2024.","Annual base salary of $675,000; eligible for annual bonus up to 100% of salary.","Received inducement options and RSUs each valued at $4M, vesting over four years.","Previously CEO of Apton Biosystems and CCO at Veracyte for ten years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240378,"accession_number":"0001193125-24-064783","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CareDx appoints Bryan Riggsbee to board as Audit Committee chair, effective March 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Riggsbee previously CFO of Myriad Genetics (2014–2024) and held senior finance roles at LabCorp and GE.","He will serve as Chair of the Audit and Finance Committee, succeeding George Bickerstaff who remains on the committee.","Annual cash retainer of $45,000 for Board service plus $20,000 for Audit Committee chair, both payable quarterly.","Initial equity grants of $200,000 fair value (options and RSUs) contingent on stockholder approval of new equity plan.","No family relationships or related party transactions; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240377,"accession_number":"0001217234-24-000032","cik":1217234,"company_name":"CareDx, Inc.","ticker":"CDNA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"CareDx reports FY2023 revenue $280.3M, exceeding guidance; Q4 net loss includes $96.3M patent accrual","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year revenue $280.3M, down 13% YoY; Testing Services revenue $209.7M, down 20%.","Q4 revenue $65.6M, down 20% YoY; net loss $118.1M, including $96.3M patent infringement accrual.","Non-GAAP net loss per share Q4 $0.17; full-year adjusted EBITDA loss $38.0M.","Cash and marketable securities $235.4M; repurchased 2.9M shares for $27.5M in 2023.","Seeking judicial review of January 2024 jury verdict on patent ‘544; Medicare coverage added for HeartCare and AlloSure Lung."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":280324000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1170087237.536101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}